| 45.85 2.94 (6.85%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 60.22 | 1-year : | 70.33 |
| Resists | First : | 51.56 | Second : | 60.22 |
| Pivot price | 43.81  |
|||
| Supports | First : | 39.47 | Second : | 32 |
| MAs | MA(5) : | 43.8 |
MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 59.2 |
|||
| 52-week | High : | 51.56 | Low : | 35.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MANE ] has closed below upper band by 39.9%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 43.79 - 44.04 | 44.04 - 44.26 |
| Low: | 40.92 - 41.24 | 41.24 - 41.52 |
| Close: | 42.45 - 42.91 | 42.91 - 43.33 |
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.
Sat, 28 Feb 2026
MANE Price History for Veradermicsorporated Stock - Barchart.com
Thu, 12 Feb 2026
Longitude investors disclose 12.5% Veradermics (MANE) stake after IPO - Stock Titan
Mon, 09 Feb 2026
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss - Business Wire
Mon, 09 Feb 2026
Assessing Veradermics (MANE) Valuation After Recent 3.6% Share Price Move - Sahm
Sat, 07 Feb 2026
Veradermics Incorporated (MANE) Gross Profit (TTM) - Zacks Investment Research
Thu, 05 Feb 2026
Veradermics’ IPO raises $256M in stellar NYSE debut - Hartford Business Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 44.6 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -131.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -13.56 |
| PEG Ratio | 0 |
| Price to Book value | -0.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -30.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|